Please enable JavaScript.  This webapp requires JavaScript to work at its best.

REFLECT study overview

 

Prof. Jeff Evans gives a concise summary of the results of the REFLECT study, a non-inferiority study comparing LENVIMA® (lenvatinib) and sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Overall survival was the primary endpoint, for which the criteris for non-inferiority was met. Prof. Evans also discusses the secondary endpoints and safety results of this study and reflects on what these results mean for prescribing in advanced HCC.

This video was recorded in March 2020. Since then the combination of atezolizumab and bevacizumab has been licensed.

Supporting documentation:

LENVIMA® 4mg hard capsules  Summary of Product Characteristics

 

 

UK-LENA-23-00098  Date of preparation March 2023